Effects of hormonal supplements on the maintenance of cardiac function in potential donor patients after cerebral death.
It is well-known that cardiac function in cerebrally dead patients rapidly deteriorates, leaving the organ unfit for donation. This study investigated whether or not cardiac function in patients with cerebral death can be maintained in a desirable condition with hormonal supplementation. In studies of changes in hormones before and after cerebral death, insulin, glucagon, triiodothyronine, thyroxine, cortisol, vasopressin, epinephrine, and norepinephrine values were measured with a lapse of time after cerebral death. Among them, triiodothyronine and cortisol levels were markedly reduced after cerebral death; therefore, these two hormones were selected as hormonal supplements. The average period from the judgment of cerebral death to cardiac arrest was 4.3 days in 12 patients with no hormonal supplement (group I) and more than 11.5 days in 4 patients with hormonal supplement (group II). This period for patients in group II was significantly longer (p less than 0.05). In 2 of the group II patients the hormonal supplementation was discontinued at the family's request, and in the other 2 patients, it was discontinued because of proposed renal donation. Hemodynamic comparisons between the two groups showed that the mean arterial pressure and the left ventricular maximum dp/dt were significantly higher (p less than 0.01) as was the cardiac index (p less than 0.05) on the 3rd day after cerebral death in members of group II. Thereafter, in group II, an excellent hemodynamic state was maintained until hormonal supplements were discontinued. We conclude that the triiodothyronine and cortisol supplements were effective in the maintenance of cardiac function in patients after cerebral death.
Taniguchi
S
S
Department of Surgery III, Nara Medical College, Japan.
Kitamura
S
S
Kawachi
K
K
Doi
Y
Y
Aoyama
N
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D001926:Brain Death / Q000097:blood / Q000503:physiopathology; D002648:Child; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D006728:Hormones / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors; D014284:Triiodothyronine / Q000008:administration & dosage / Q000097:blood*
D006728:Hormones; D014284:Triiodothyronine; D006854:Hydrocortisone